Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
- 18 February 2021
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 397 (10277), 875-877
- https://doi.org/10.1016/s0140-6736(21)00448-7
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Postvaccination COVID-19 among Healthcare Workers, IsraelEmerging Infectious Diseases, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Who should be prioritised for COVID-19 vaccines?The Lancet, 2020